ProShares - Ultra Nasdaq ... (BIB)
NASDAQ: BIB
· Real-Time Price · USD
55.58
-0.29 (-0.53%)
At close: Aug 18, 2025, 3:59 PM
-0.53% (1D)
| Bid | 54 |
| Market Cap | 50.74M |
| AUM | 55.31M |
| NAV | 54.76 |
| EPS (ttm) | 1.95 |
| PE Ratio (ttm) | 28.50 |
| Shares Out | 913.01K |
| Inception Date | Apr 7, 2010 |
| Ask | 57 |
| Volume | 10.22K |
| Open | 56.39 |
| Previous Close | 55.87 |
| Day's Range | 55.58 - 56.48 |
| 52-Week Range | 33.78 - 69.17 |
| Holdings | 274 |
| Expense Ratio | 1.14% |
About BIB
ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index.
Asset Class Equity
Ticker Symbol BIB
Inception Date Apr 7, 2010
Provider Proshares
Website Fund Home Page
Exchange NASDAQ
Top 10 Holdings 61.78% of assets
| Name | Symbol | Weight |
|---|---|---|
| Net Other Assets (li... | 25.82% | |
| Treasury Bill | 8.80% | |
| Gilead Sciences, Inc... | GILD | 4.93% |
| Amgen Inc. | AMGN | 4.72% |
| Vertex Pharmaceutica... | VRTX | 4.08% |
| Regeneron Pharmaceut... | REGN | 4.04% |
| Alnylam Pharmaceutic... | ALNY | 3.38% |
| Astrazeneca PLC | AZN | 3.10% |
| Insmed Incorporated | INSM | 1.54% |
| Argenx Se | ARGX | 1.37% |
Dividends Dividend Yield 1.85%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Jun 25, 2025 | $0.1706 | Jul 1, 2025 |
| Mar 26, 2025 | $0.1309 | Apr 1, 2025 |
| Dec 23, 2024 | $0.3964 | Dec 31, 2024 |
| Sep 25, 2024 | $0.1529 | Oct 2, 2024 |
| Jun 26, 2024 | $0.2648 | Jul 3, 2024 |
1 year ago · investorplace.com
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichSome of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom. On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.
2 years ago · investorplace.com
The 7 Best ETFs to Buy to Cover 2023's Biggest Investing OpportunitiesThese are some of the best ETFs to buy and hold heading into New Year 2023. Rather than being completely tied to the ebb and flow of single-stock ideas, you can gain access to a broad number of simila...
